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Abstract
Anoikis is a programmed cell death induced upon cell detachment from
extracellular matrix, behaving as a critical mechanism in preventing adherent-
independent cell growth and attachment to an inappropriate matrix, thus avoiding
colonization of distant organs. Cell adhesion plays an important role in neoplastic
transformation. Tumors produce several molecules that facilitate their proliferation,
invasion and maintenance, especially proteoglycans. The syndecan-4, a heparan
sulfate proteoglycan, can act as a co-receptor of growth factors and proteins of the
extracellular matrix by increasing the affinity of adhesion molecules to their specific
receptors. It participates together with integrins in cell adhesion at focal contacts
connecting the extracellular matrix to the cytoskeleton. Changes in the expression
of syndecan-4 have been observed in tumor cells, indicating its involvement in
cancer. This study investigates the role of syndecan-4 in the process of anoikis and
cell transformation. Endothelial cells were submitted to sequential cycles of forced
anchorage impediment and distinct lineages were obtained. Anoikis-resistant
endothelial cells display morphological alterations, high rate of proliferation, poor
adhesion to fibronectin, laminin and collagen IV and deregulation of the cell cycle,
becoming less serum-dependent. Furthermore, anoikis-resistant cell lines display a
high invasive potential and a low rate of apoptosis. This is accompanied by an
increase in the levels of heparan sulfate and chondroitin sulfate as well as by
changes in the expression of syndecan-4 and heparanase. These results indicate
that syndecan-4 plays a important role in acquisition of anoikis resistance and that
the conferral of anoikis resistance may suffice to transform endothelial cells.
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Introduction
The extracellular matrix (ECM) affects many aspects of cell behavior, including
the migratory properties of cells, their morphology, growth characteristics, and
differentiation [1, 2]. Most normal endothelial cells require continuous signals
from their environment to survive (mediated via adhesive interactions with other
cells or extracellular matrix proteins) and loss of contact induces a specialized
form of apoptosis, anoikis. The initiation and execution of anoikis is mediated by
different pathways, all of which merge into the activation of caspases and
downstream molecular pathways, culminating in the activation of endonucleases,
DNA fragmentation and cell death [3]. As a result, failure to execute the anoikis
program could result in adherent cells surviving under suspension conditions or
proliferating at ectopic sites where the ECM proteins are different from the
original ones. This deregulation in anoikis execution is emerging as a hallmark of
cancer cells and contributes to the formation of metastasis in distant organs [4].
Indeed in neoplastic cells, alterations in cell-cell adhesion molecules, protein
kinases or phosphatases, integrin-associated signalling molecules or apoptosis
regulators can lead to resistance to the physiologically occurring anoikis,
conferring by this way a constitutive pro-survival signal allowing dissemination of
metastatic cancer cells [5–9].
For all steps in the metastatic cascade, the interaction of cells with the ECM is
crucial [10]. Integrins are important mediators of cell adhesion to extracellular
ligands and can transduce biochemical signals both into and out of cells [11, 12].
Vascular endothelial cells have been reported to express integrins a1b1, a2b1,
a3b1, a5b1, a6b1, a6b4, avb3 and avb5 [11]. Integrins containing b1, b3 and b5
subunits interact with the microfilament system in focal adhesions [12]. Recent
study provides evidence that integrin b5 facilitates cancer cell migration,
anchorage-independent growth and tumor angiogenesis [13].
It is now becoming clear that additional transmembrane components can
modify integrin-mediated adhesion. Syndecan-4 is a transmembrane heparan
sulfate proteoglycan whose external glycosaminoglycan chains can bind extra-
cellular matrix ligands and whose core protein cytoplasmic domain can signal
during adhesion [14, 15]. The syndecans, including syndecan-1 and -4, selectively
bind to various matrix components, growth factors and anticoagulant proteins
through heparan sulfate glycosaminoglycan chains, and these interactions may
facilitate important biological activities [16, 17]. Syndecan-1, -2, -4 and glypican-1
are expressed by vascular endothelial cells [18–20]. Endothelial cell line derived
from rabbit aorta (EC) express mainly syndecan-4 [21–23].
Syndecan-4 is fundamental in cell adhesion and this adhesion plays important
roles in the normal functions of cells, contributing to cellular organization and
structure, proliferation and survival. This heparan sulfate proteoglycan is widely
expressed but usually at low levels in normal tissue and unique among the
syndecan family members to localize at sites of cell–matrix adhesions, specifically
concentrated into focal adhesions together with integrins [24–27]. Its cytoplasmic
domain can both bind to and potentiate the phospholipid-mediated activity of
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PKCa, which can itself be a focal adhesion component. Indeed, the insertion of
syndecan-4 into focal adhesions requires PKC activity, suggesting that it may bind
activated PKCa and both localize it to forming adhesions and potentiate its
activity [28–31].
The expression of the syndecans can be altered under certain pathophysiolo-
gical conditions, including the processes of tumor onset, progression and
metastasis [32, 33]. Significant structural changes of heparan sulfate and
overexpression of syndecan-4 were observed in the EJ-ras-transfected cells [21].
Upregulation of syndecan-4 has been noted in some carcinomas [34, 35] and such
overexpression may correlate with increased tumor cell proliferation [36, 37]. So,
alterations in the level of expression of the protein core, as well as heparan sulfate
structure and/or density on heparan sulfate proteoglycans (HSPGs), can
potentially make cancer cells highly versatile in modulating their behavior [38].
These and other results led us to investigate the role of syndecan-4 in the
process of anoikis and cell transformation. We now report that anoikis-resistant
endothelial cells display morphologic and molecular alterations, in particular, the
overexpression of syndecan-4.
Our findings suggest that syndecan-4 may be involved in acquisition of
resistance to detachment-induced cell death (anoikis resistance) in endothelial
cells, thus contributing to cell transformation.
Materials and Methods
Reagents and Antibodies
Fibronectin (341635) and laminin (CC095) were acquired from Merck Millipore
(Massachusetts, USA). Collagen type IV (354233) was obtained from BD
Pharmingen (San Diego, CA, USA). Rabbit polyclonal antibody syndecan-4 (H-
140) (sc-15350), rabbit polyclonal antibody HPA1 (H-80) (sc-25825) and mouse
monoclonal antibody GAPDH (SC-66163) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Rabbit monoclonal antibody integrin b5
(D24A5) was purchased from Cell Signaling Technology, Inc. (Danvers, MA,
USA). Alexa Fluor 488 phalloidin was obtained from Life Technologies (New
York, USA). HRP-linked goat anti-mouse IgG (A4416) and HRP-linked goat anti-
rabbit IgG (A6154) secondary antibodies were obtained from Sigma-Aldrich (St
Louis, USA). Goat anti-rabbit IgG (H+L) highly cross-adsorbed labeled with
Hilyte Fluor 594 (61056-05-H594) secondary antibody was obtained from
Anaspec (Fremont, CA, USA).
Cell Culture
Endothelial cell line derived from rabbit aorta (EC) [39], EC transfected with EJ-
ras oncogene (EJ-ras EC) [21] and EC resistant to anoikis (Adh12EC and
Adh22EC) were maintained in F12 medium (Life Technologies - New York, USA)
supplemented with 10% fetal calf serum (FCS) (Athena, Campinas, SP, Brazil) at
Syndecan-4 and Anoikis Resistance
PLOS ONE | DOI:10.1371/journal.pone.0116001 December 30, 2014 3 / 23
37 C˚, 2.5% CO2. Serum-starved cultures were obtained by maintaining the cells in
the presence of F12 containing 0.2% FCS, for 48 h at 37 C˚, 2.5% CO2 before
stimulus with 10% FCS.
Anchorage-Independent Growth Assays
Endothelial cells derived from rabbit aorta (EC) (105 cells/ml) were plated on 1%
agarose and cultured for 96 hours in F12 medium (Life Technologies - New York,
United States) supplemented with 10% FCS (Campinas, Brazil) at 37 C˚, 2.5%
CO2. Small spheroids were collected by decantation and plated on standard
culture plates, favoring cell adhesion. Cells were allowed to proliferate to
subconfluent growth. The deadhesion (spheroid formation) cycle was repeated for
four or five times; after the last deadhesion step, spheroids were counted and
plated by limiting dilution (0.5–1 spheroid/well) [40]. Two clones resistant to
anoikis (Adh12EC and Adh22EC) were selected for more detailed studies.
Cell Growth Analysis
Equal numbers (56104) of EC, EJ-ras EC, Adh12EC and Adh22EC cells were
added into the different cell culture dishes and maintained in F12 medium (Life
Technologies - New York, USA) supplemented with 10% fetal calf serum (FCS)
(Athena, Campinas, SP, Brazil) at 37 C˚, 2.5% CO2. Every two days, cells were
removed from the dishes, washed with PBS and, counted using a Neubauer
chamber. Triplicate dishes were used for each time point (0, 2, 4, 6 and 8 days).
Each experiment was repeated three times.
Invasion Assay
The invasion assays was performed on 24-well plates using Polycarbonate
Transwell of 8 mm pore size (Corning Inc. Lowell, MA, USA) coated with ECL cell
attachment matrix (entactin, collagen IV and laminin) (1 mg/ml) (Merck
Millipore, Massachusetts, USA). Briefly, the coated inserts were hydrated with
warm F12 without serum in 2.5% CO2 at 37 C˚ for two hours. A total of 5610
4
endothelial cells were seeded into the upper chamber containing F12 without
serum, and the lower chamber contained F12 with 10% FCS. The cells were
incubated at 37 C˚ in 2.5% CO2 for 48 h. Non-invading cells were removed from
the upper membrane by scrubbing with a cotton swab. Invading cells were fixed
with 1% formaldehyde at room temperature for 30 minutes, stained with 1%
toluidine blue (Sigma-Aldrich, St Louis, USA) dissolved in 1% sodium tetraborate
for 15 minutes, and visualized under a light microscope (Carl Zeiss, Jena,
Germany). The number of stained cells was counted in 10 microscope fields (206
magnification). Each experiment was repeated three times.
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Annexin V-FITC/PI Staining Assay
Apoptosis was assessed by the binding of annexin V conjugated with fluorescein
isothiocyanate (FITC) to phosphotidylserine, which is externalized to the outer
leaflet of the plasma membrane early during induction of apoptosis. Briefly, EC
cells and its derived clones (16106) were resuspended in the binding buffer
provided in the annexin V-FITC apoptosis detection kit II (BD Pharmingen, San
Diego, CA, USA) and reacted with 5 mL of annexin V-FITC reagent and 5 mL of
propidium iodide (PI) for 30 min at room temperature in the dark. Stained cells
were analyzed by flow cytometry (FACSCalibur - Becton, Dickinson and Co,
Franklin Lakes, NJ, USA), using the FlowJo program (Tree Star Inc., Ashland, OR,
USA). Each experiment was repeated three times.
BrdU Incorporation and Flow Cytometry for Cell Cycle
For BrdU incorporation, serum starved cultures were incubated with BrdU 10 mM
in the absence or in the presence of 10% fetal calf serum (FCS) for 20 hours. BrdU
uptake was determined essentially as recommended by the kit manufacturer
(BrdU Cell Proliferation Assay - Merck Millipore – MA, USA). For cytometric
DNA analysis, quiescent cultures were stimulated with 10% FCS for different
periods of time. The cells were detached from the culture plate using trypsin and
submitted to flow cytometric analysis as previously described [41] using the
FlowJo software (Tree Star Inc., Ashland, OR, USA). Each experiment was
repeated three times.
Flow Cytometry for Surface Expression
Endothelial cells (16106 cells) were fixed with 2% paraformaldehyde and
permeabilized with 0.01% saponin. The cells were then incubated for 2 h with the
primary antibody (rabbit anti-syndecan-4 1: 300 and rabbit anti-integrin b5 1:
200). Afterwards, the cells were incubated for 1 h with goat anti-rabbit IgG-Hilyte
Fluor 594-conjugated as a secondary antibody (1:300). All antibodies were diluted
in PBS with 1% BSA. Cells stained only with secondary antibody were used to
subtract background fluorescence. Data analyses were performed on a BD
FACSCalibur flow cytometer (BD Pharmingen, San Diego, CA, USA) using the
WinMDI 2.9 software (J. Trotter, Scripps Research Institute, La Jolla, CA). The
data represent the results of two different experiments.
Adhesion Assays
Ninety six-well tissue culture plates (Corning/Costar – New York, USA) were
submitted to attach to substrate (5, 10, 20 or 30 mg/ml of fibronectin, laminin or
collagen IV) for 2 h at 37 C˚. The plates were washed with PBS and blocked with
1% BSA in PBS for 1 h at 37 C˚. Endothelial cells (56104 in F12-medium) were
added to the plates and submitted to attach to substrate for 3 h at 37 C˚. At the end
of incubation, the unattached cells were removed by washing the plates with PBS.
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Attached cells were fixed in methanol for 20 min, and stained with 0.8% crystal
violet (Sigma-Aldrich – St Louis, USA) dissolved in 20% ethanol, and washed five
times with PBS. The dye was then eluted with 50% ethanol 0.1 M sodium citrate,
pH 4.2 and measured for absorbance at 540 nm using a microplate reader EZ
Read 400 (Biochrom – MA, USA). For control, the non-adhesive substrate was
prepared by coating the wells with 1% BSA for 60 min at 37 C˚. The experiments
were performed in triplicates for each dose and repeated three times in different
days.
Western Blotting
Endothelial cells were lysed in buffer [50 mM Tris-HCl, pH 7.4, 1% Tween 20 and
Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific Inc.,
Rockford, IL, USA)] for 2 h at 4 C˚. The homogenates were spun at 18,000 g for
5 min, and the supernatant was collected. Proteins were quantified using the BCA
Protein Assay Kit (Thermo Fisher Scientific Inc., Rockford, IL, USA). Equal
amounts of protein extracts (20 mg) were subjected to 10% SDS-PAGE and
blotted onto a PVDF membrane (Merck Millipore, Massachusetts, USA). After
blocking, the membrane was incubated with the primary antibody (rabbit anti-
syndecan-4 1: 1000; rabbit anti-integrin b5 1: 1000, rabbit anti-HPA1 1: 1000 and
mouse anti-GAPDH 1:500) diluted in blocking buffer overnight at 4 C˚ and
followed by incubation with secondary antibodies (1:10000) for 1 h at room
temperature. The samples were detected by enhanced chemiluminescence using
the SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific
Inc., Rockford, IL, USA). An Alliance mini photodocumentation system from
UVITEC (Cambrige, UK) was used to scan the films, and the UVIBAND MAX
v1503b software (UVITEC - Cambrige, UK) was used to measure the amount of
protein detected by each antibody. The experiments were performed in duplicates
and repeated twice.
Immunocytochemistry
Cells were cultured on 13.0 mm diameter glass coverslips (56103 cells/coverslip)
in 24 well plates for 2 days followed by fixation with 2% formaldehyde in PBS
(pH 7.4) for 20 min at room temperature. The cells were washed four times with
PBS and once with PBS containing 0.1 M glycine. They were then permeabilized
with PBS containing 1% BSA and 0.01% saponin for 15 min at room
temperature. After this step, the cells were washed with PBS and incubated with
rabbit anti-integrin b5 (1:200) and Alexa Fluor 488 phalloidin (1:250) diluted in
PBS containing 0.01% saponin for 1 h at room temperature. After washing, the
cells were incubated with goat anti-rabbit labeled with Hilyte Fluor 594 (1:300)
and DAPI (2 mg/ml) in PBS containing 0.01% saponin for 20 min at room
temperature. The cells were washed and mounted in Fluoromount-G (2:1) diluted
in PBS and examined using an inverted confocal laser-scanning microscope (Leica
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TCS SP8, Leica Microsystems, Wetzlar, DE). Each figure shown in the results
section corresponds to the best of two experiments.
Extraction and Identification of Sulfated Glycosaminoglycans
Sulfated glycosaminoglycans synthesized by the cells were metabolically labeled
with [35S]-sulfate (150 mCi/ml) in F-12 medium for 18 h at 37 C˚ in 2.5% CO2
atmosphere. Afterwards, the culture medium was removed and the cells washed
twice with F-12 medium and scrapped from the dish with 3.5 M urea in 25 mM
Tris-HCl pH 7.8. Both to the medium and the cell extract 100 mg of carrier
heparan sulfate, dermatan sulfate and chondroitin sulfate were added. The
radioactive glycosaminoglycan free chains were prepared from the cell lysates and
from the culture supernatants by incubation with 4 mg of maxatase (Biocon do
Brasil Ltda, Rio de Janeiro, Brazil) for 4 h at 60 C˚. The [35S]-sulfated
glycosaminoglycans were identified and quantified by agarose gel electrophoresis,
as previously described in [42, 43]. The radioactive compounds were located by
exposure of the gels (after fixation, drying and staining) to Cyclone storage
phosphor screen (Packard Institute – Meriden, USA). For quantification, the
radioactive bands were scrapped off the agarose gels, and counted in 5 ml of
Ultima Gold (Packard) in a liquid scintillation spectrometer (TRI-CARB 2100TR,
Packard). Protein was determined by the Coomassie blue assay. The experiments
were performed in duplicates and repeated three times.
RT-PCR
For RT-PCR, total RNA was isolated from the endothelial cells with the Trizol-
reagent from Invitrogen (Carlsbad, CA, USA), and quantitated by spectro-
photometer. RT-PCR was prepared using SuperScript One-Step RT-PCR with
Platinum Taq (Life Technologies, New York, USA), according to the
manufacturer’s instructions. All sequences available from the GenBankTM were
included in the search for possible primer binding regions. Initially, the reverse
transcription was performed at 45 C˚ for 30 min. The following 59 and 39 primers
were used in RT-PCR and the reaction performed for 40 cycles as specified for
each pair of primers. Syndecan-4: Rev (59-GAGTCGATTCGAGAG ACAGAG-39);
Fwd (59-GTCCTTCTTCTTCATGCGGTAC-39), denaturation at 94 C˚ for 1 min,
annealing at 55 C˚ for 1 min, extension at 72 C˚ for 2 min). The amplified product
is 459 bp in size. GAPDH: Rev (59-ATGCCATCACTGCCACCCAG-39); Fwd (59-
CATGCCAGTGAGCTTCCCGTT-39), denaturation at 94 C˚ for 1 min, annealing
at 55 C˚ for 1 min, extension at 72 C˚ for 1 min. The amplified product is 158 bp in
size. Primers were synthesized by GENSET Corporation (San Diego, USA). After
cycling, each sample was fractionated on 1% agarose gel in Tris-acetate buffer,
stained with ethidium bromide, and visualized by UV fluorescence. The sizes of
RT-PCR products were determined using the 100 bp DNA ladder (Life
Technologies, New York, USA). The products were digitalized using Alliance 4.7
Video Documentation System (Uvitec Cambridge – Cambridge, UK), and
Syndecan-4 and Anoikis Resistance
PLOS ONE | DOI:10.1371/journal.pone.0116001 December 30, 2014 7 / 23
quantitative analysis performed with UviBand Software (Uvitec Cambridge –
Cambridge, UK). The experiment was repeated four times.
Quantitative Real-Time PCR (qPCR)
For quantitative PCR (qPCR), 10 mg of total RNA per sample was reverse
transcribed to cDNA with anmiScript Reverse Transcription Kit (Qiagen, Hilden,
DE) and then 50 ng of cDNA was analyzed using the miScript SYBR Green Kit
(Qiagen, Hilden, DE) with a ABI 7500 real-time PCR instrument (Applied
Biosystems, Foster, CA, USA), according to the manufacturer’s instruction,
respectively. The primers are used as follow: syndecan-4 Fwd
(59-AGCCTGGGCAGGTCGTGTCT-39) and syndecan-4 Rev
(59-GTGGTTCCCCTCACCGCAGC-39); heparanase Fwd
(59-CAAGAAGGTTGGGTTCTGAGGAGA-39) and heparanase Rev
(59-GCATCGAAGGTG AGCAAGGATGG-39); GAPDH Fwd
(59-CGCTTCGCTCTCTGCTCCTCC-39) and GAPDH Rev
(59- TGGTGACCAGGCGCCCAATAC-39). PCR was performed at 95 C˚ for 15 s
and 60 C˚ for 60 s for 40 cycles. GAPDH was used as an internal standard to
normalize mRNA levels for differences in sample concentration and loading. Fold
changes in the expression of each target mRNA relative to GAPDH was calculated
based on the threshold cycle (Ct) as 22D (DCt), where DCt5Ct target- Ct
GAPDH and D (DCt)5DCtAdh-EC2DCtEC. The post-amplification melting
curve analysis was performed to confirm whether the nonspecific amplification
was generated from primer-dimers. Quantitative PCR reactions were performed
in triplicate. Results were derived from a total of four independent experiments.
Statistical Analysis
All data are expressed as the mean ¡ standard error of the mean. Statistical
significance was assessed using analysis of Student’s t-test. P values ,0.05 were
considered statistically significant.
Results
Characterization of Anoikis-Resistant Endothelial Cells
Endothelial cells were submitted to stressful conditions by blocking adhesion to
substrate, as described in methods. As expected for a nontumorigenic
immortalized cell line, the great majority of these cells underwent apoptosis
induced by adhesion blockade (anoikis). After cultivating endothelial cells in
agarose-coated plates for 96 hours, few spheroids were observed. Anoikis-resistant
EC cells were cultured in adherent conditions and submitted to new deadhesion
cycles. Distinct lineages (Adh12EC, Adh22EC, Adh32EC, Adh42EC, Adh52EC
and others) were obtained by limiting dilution after four deadhesion cycle of EC
cells (1 spheroid/well) and two clones (Adh12EC and Adh22EC) were then
selected for more detailed studies.
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The selected clones were analyzed with respect to cell morphology, cell growth
and adhesiveness. EC (not tumorigenic) and EJ-ras EC (tumorigenic) were used as
controls. All cell lines were maintained in culture and observed under a phase
contrast microscope (Fig. 1A). Altered morphology was observed in all EC–
derived cell lines, which demonstrated stable phenotypic characteristics. Cell lines
obtained after submitting EC cells to adhesion impediment cycles are arranged in
several layers of cells, did not show density inhibition or growth arrest upon
serum starvation, as described for EJ-ras EC cells [21]. In contrast, the parental
line display in a cell monolayer, showing density inhibition. Recent study have
implicated integrin b5 in tumor growth in anchorage-independent condition
[13]. To investigate the role of integrin b5 in anoikis resistance, we analyzed the
expression of integrin b5 in all cell lines. Actin filaments and integrin b5 were
analyzed by confocal fluorescence microscopy (Fig. 1B). Anoikis-resistant
endothelial cells showed irregular shape, variable disorganization and increase in
the number of actin filaments. No changes in the cellular distribution of integrin
b5 were observed. Western blot analysis showed that protein expression levels of
integrin b5 were similar in all cell lines (Fig. 1C). These data were corroborated by
flow cytometric analysis (Fig. 1D). In addition, the cell growth rate nearly doubled
for EJ-ras EC, Adh12EC and Adh22EC cells in relation to EC cells (Fig. 2A). The
cell lines obtained after four deadhesion steps showed lower adhesiveness to
fibronectin, laminin and collagen IV in relation to EC cells. Similar results were
observed in EJ-ras EC cells (Figs. 3A, B and C).
BrdU Incorporation and Flow Cytometry of Anoikis-Resistant
Endothelial Cells
Serum-starved EC, EJ-ras EC, Adh12EC and Adh22EC cells were labeled with
BrdU 10 mM in the absence or in the presence of 10% FCS for 20 hours.
Adh12EC, Adh22EC and EJ-ras EC cells incorporate BrdU practically to the same
extent, both in the presence and in the absence of FCS, as opposed to the parental
cells, which are highly dependent on serum for BrdU incorporation (Fig. 2B).
The results obtained with flow cytometry confirm these observations. Serum-
starved EC, EJ-ras EC, Adh12EC and Adh22EC cells cycle was analyzed by flow
cytometry based on their DNA content. EC and EC–derived cell lines were
stimulated to enter the S phase by FCS addition. However, the growth response to
FCS exhibited by the parental endothelial cells is not present in the Adh12EC,
Adh22EC and EJ-ras EC cells (Table 1, Fig. 2C). Anoikis-resistant endothelial
cells are not synchronized by serum starvation, as described for EJ-ras EC cells
[21].
Invasion Capacity and Percentage of Apoptosis in Anoikis-
Resistant Endothelial Cells
As anoikis resistance is a key factor in tumor metastasis, we decided to analyze the
invasiveness and apoptosis rates in anoikis-resistant endothelial cells. To analyze
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the invasiveness, EC, EJ-ras EC, Adh12EC and Adh22EC cells were added into the
plates using polycarbonate transwell coated with ECL cell attachment matrix
(Merck Millipore). As shown in Fig. 4A, invasion chamber analysis demonstrated
that, compared to EC cells (100%), the invasion rate of Adh12EC, Adh22EC and
EJ-ras EC cells were 156%, 193% and 91%, respectively. To determine the
percentage of apoptotic cells, EC, EJ-ras EC, Adh12EC and Adh22EC cells were
harvested and stained with Annexin V-FITC and propidium iodide (PI) (BD
Pharmingen). Stained cells were analyzed by flow cytometry. The results obtained
with flow cytometry revealed a significant decrease in apoptosis in Adh12EC,
Adh22EC and EJ-ras EC cells (3.5%, 3.2% and 2.2%, respectively) compared with
EC cells (6.4%) (Fig. 4B). The results indicate that anoikis-resistant endothelial
cells exhibit characteristics of tumorigenic cells as high invasive potential and low
rate of apoptosis.
Heparan Sulfate and Chondroitin Sulfate Expression Is Increased
in Anoikis-Resistant Endothelial Cells
Endothelial cells were exposed to [35S]sulfate for 18 h and aliquots of the cell
extracts and of the culture medium were treated with protease and subjected to
electrophoresis, as described in Methods. Fig. 5A shows an increase in the
expression of heparan sulfate and chondroitin sulfate present in the Adh-EC and
EJ-ras EC cells, when compared to the parental line. An increase in the amount of
heparan sulfate and chondroitin sulfate secreted to the medium was also observed.
The quantitative data of these experiments (Fig. 5B) indicate that significant
differences are found in the levels of chondroitin sulfate present in the cells and in
the levels of heparan sulfate secreted to the medium by parental, Adh-EC and EJ-
ras EC cells. These data led us to investigate the levels of syndecan-4 and
heparanase in endothelial cells.
Syndecan-4 and Heparanase Expression in Anoikis-Resistant
Endothelial Cells
In order to examine the gene expression levels of syndecan-4 (syn-4) and
heparanase (HPSE) by parental, Adh-EC and EJ-ras EC cells, we used RT-PCR
and qPCR analyses. It is clear that anoikis-resistant endothelial cells show higher
levels of expression of syndecan-4 (Fig. 6A). The relative values of expression of
syndecan-4 normalized with respect to GAPDH levels show a 1.55, 1.71 and 1.59-
Fig. 1. Morphologic characteristics and integrin b5 expression of EC-derived cell lines. (A) Parental (EC), EJ-ras transfected endothelial cells (EJ-ras
EC), and anoikis-resistant endothelial cells (Adh12EC and Adh22EC) were maintained in culture for 7 days and photographed under a Nikon phase
contrast microscope. Bar5100 mm. (B) Immunofluorescent analysis of F-actin and integrin b5 in EC, EJ-ras EC, Adh12EC and Adh22EC cells. Actin
filaments were stained with Alexa Fluor-488 phalloidin (green) and integrin b5 was stained with anti-integrin b5 antibody followed by secondary Hilyte Fluor-
594-labelled antibody (red). Nucleus stained with DAPI (blue). Scale bar: 50 mm. (C) The protein expression levels of integrin b5 were assessed by western
blot analysis. GAPDH is shown as a protein loading control. Histogram depicting integrin b5 protein levels normalized to GAPDH. (D) Flow cytometry
analysis for cell surface presentation of integrin b5 in EC, EJ-ras EC, Adh12EC and Adh22EC cells. Filled histogram, cells treated with anti-integrin b5 and
secondary antibody; opened histogram, cells treated only with secondary antibody. In B, C and D, two independent experiments were performed in
duplicates. The bars represent the standard error.
doi:10.1371/journal.pone.0116001.g001
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fold increase for the Adh1-EC, Adh2-EC and EJ-ras EC cells, respectively, when
compared to the parental cells (Fig. 6B). As shown in Fig. 6E, the qPCR
demonstrated a statistically significant difference in the expression of heparanase
in the parental, Adh-EC and EJ-ras EC cells. Heparanase levels were increased
16.4, 5.3 and 17.3-fold in Adh1-EC, Adh2-EC and EJ-ras EC cells, respectively,
Fig. 2. Proliferation and cell cycle of EC-derived cell lines. (A) Growth curves of EC, EJ-ras transfected cells (EJ-ras EC), and EC anoikis resistant
(Adh12EC and Adh22EC). (B) BrdU incorporation for 20 h. Serum-starved EC, EJ-ras-transfected cells (EJ-ras EC) and EC anoikis resistant (Adh12EC and
Adh22EC) were serum-starved, as described in Methods, and stimulated to proliferate by the addition of 10% FCS. (C) Cell cycle distribution of EC, EJ-ras
transfected cells (EJ-ras EC), and EC anoikis resistant (Adh12EC and Adh22EC). Histograms show the proportion of cells at different stages in the cell
cycle (DNA content of propidium iodide–stained nuclei) analyzed by flow cytometry. ABS: absorbance. All experiments were repeated three times. The bars
represent the standard error. * P#0.05.
doi:10.1371/journal.pone.0116001.g002
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when compared to the parental cells. In addition, we examined the protein
expression levels of syndecan-4 in all cell lines using western blot (Fig. 6C) and
flow cytometry (Fig. 6D) techniques and confirmed that EC–derived cell lines
express more syndecan-4 than parental cells. S1 Fig. shows the ratio of active
HPSE:pro-enzyme HPSE (active HPSE:pro-enzyme HPSE/GAPDH) determined
Fig. 3. Adhesion rate of EC-derived cell lines. (A), (B) and (C) Assay adhesion of parental (EC), EJ-ras transfected endothelial cells (EJ-ras EC), and
anoikis-resistant endothelial cells (Adh12EC and Adh22EC) on fibronectin, laminin, and collagen IV, respectively. ABS: absorbance. The experiments were
performed in triplicates and repeated three times. The bars represent the standard error. * P#0.05.
doi:10.1371/journal.pone.0116001.g003
Table 1. Cell cycle of EC-derived cell lines.
EC (%) EJ-ras EC (%) Adh12EC (%) Adh22EC (%)
Time (h)a G0/G1 S G2/M G0/G1 S G2/M G0/G1 S G2/M G0/G1 S G2/M
0 76,7 2,5 20,8 57,7 14,9 27,4 57,7 11,7 30,6 64,4 12,5 23,1
4 63,8 9,2 27,0 54,6 19,9 25,5 57,8 13,9 28,3 59,5 16,8 23,7
12 60,2 14,2 25,6 53,8 19,0 27,3 54,9 24,7 20,4 53,1 21,2 25,7
20 64,5 8,2 27,3 55,4 17,1 27,5 59,4 20,1 20,5 52,8 17,9 29,3
aCells were kept in 0.2% FCS for 48 h, and stimulated with 10% FCS. The cells were harvested for flow cytometric analysis of DNA content at various time
periods after stimulation. The numbers represent an average of three different experiments with an error of 5%.
doi:10.1371/journal.pone.0116001.t001
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by Western Blot analysis. It was demonstrated that Adh1-EC and Adh2-EC cells
have an increase of active HPSE (50 kDa), respectively, 11% and 21%, while EJ-
ras EC cells present an increase of 26%, compared to EC cells. These combined
results indicated that EJ-ras EC cells, as well as, both anoikis-resistant endothelial
cells (Adh1-EC and Adh2-EC), present higher levels of active HPSE comparing to
EC cells. Interestingly, increased ratio of active HPSE:pro-enzyme HPSE in
different cell lineages (S1 Fig.), follows the same profile of protein levels of
syndecan-4 (Fig. 6C).
Discussion
In the absence of attachment to ECM or upon cell adhesion to inappropriate
location, cells undergo a particular type of apoptosis, termed anoikis. Anoikis has
been described in several cell types, although it appears that cells of different tissue
origin activate dissimilar pathways leading to anoikis. The physiological relevance
of anoikis is confirmed by the fact that cancer cells lines, rather than normal
epithelial cells, are usually not sensitive to anoikis, and many have developed
anchorage independence, meaning they do not require adhesion to ECM to
proliferate and survive [44, 45]. Here, we show that repetitive adhesion blockade
events can lead to endothelial cell transformation. Anoikis-resistant endothelial
cells (Adh-EC) display morphological alterations, high rate of proliferation, poor
adhesion to fibronectin, laminin and collagen IV and deregulation of the cell
cycle, becoming less serum-dependent, as shown by the ratios of BrdU
incorporation and flow cytometry in the absence and in the presence of FCS, in
contrast with the parental cells. Furthermore, EC–derived cell lines display a high
Fig. 4. Invasion capacity and percentage of apoptosis in EC-derived cell lines. (A) Values of relative invasiveness of EJ-ras EC, Adh12EC and
Adh22EC cells normalized with those of EC cells (100%). Invasion activity of EC-derived cell lines was analyzed by using a Transwell coated with ECL cell
attachment matrix as described in Methods. (B) Percentage of apoptotic cells detected by Annexin V-FITIC/PI double staining method in EC, EJ-ras
transfected cells (EJ-ras EC), and EC anoikis resistant (Adh1vEC and Adh22EC) cells. All experiments were repeated three times. The bars represent the
standard error. * P#0.05.
doi:10.1371/journal.pone.0116001.g004
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invasive potential and a low rate of apoptosis. This is accompanied by an increase
in the levels of heparan sulfate and chondroitin sulfate as well as by changes in the
expression of syndecan-4 and heparanase. Similar results were observed in
endothelial cells transfected with EJ-ras oncogene (EJ-ras EC) [21].
Previous studies have shown that repetitive adhesion blockade events are
sufficient to induce malignant transformation in nontumorigenic immortalized
melanocytes [40]. Multiple factors with frequently overlapping functions have
been reported to confer anoikis suppression to tumor cells by stimulating survival
pathways. One, however, could propose that anoikis resistance not only confers
the cell with the ability to survive without attachment to the ECM but may also
provide a molecular signature that secures their successful migration, invasion,
and metastasis to distant sites [46]. Endothelial cells are protected by anoikis when
they are adherent on permissive ECM proteins.
Tumor progression resulting in cancer metastasis is a multistep process, which
is dependent on dynamic changes in adhesive and migratory ability of tumor cells.
Fig. 5. [35S] sulfated glycosaminoglycans synthesized by EC, EJ-ras EC, Adh12EC and Adh22EC cells. (A) Endothelial cells were exposed to
[35S]sulfate for 18 h. The radioactive glycosaminoglycan-free chains were prepared, from both cells and conditioned medium, by incubation with proteolytic
enzyme. Aliquots were subjected to electrophoresis for 60 min in 0.6% agarose (0.05 M 1,3-diaminopropane-acetate buffer pH 9.0) [38, 39]. The radioactive
compounds were located in the gels, as described in Methods. CS: chondroitin sulfate; DS: dermatan sulfate; HS: heparan sulfate; OR: origin. (B)
Quantification of the experiment shown in A. For further details, see Methods. The experiments were performed in duplicates and repeated three times. EC:
parental endothelial cells; EJ-ras EC: EJ-ras transfected endothelial cells; Adh12EC and Adh22EC: anoikis-resistant endothelial cells. The bars represent
the standard error. * P#0.05.
doi:10.1371/journal.pone.0116001.g005
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Integrins are the major cell surface receptors mediating cell-to-extracellular matrix
adhesion and are involved in the regulation of focal adhesion turnover and
survival signaling, which are key events in the process of tumor growth and tumor
cell migration [47]. Cooperatively with the integrins, cell adhesion is also
organized by cell surface heparan sulfate proteoglycans, syndecans [48]. Of all 4
syndecan genes, syndecan-4 (SDC4) is the only ubiquitously expressed member
and functions as an integrin co-receptor in cell adhesion–promoting mitogen-
activated protein kinase signaling pathways [48, 49].
Many endothelial cells express HSPGs at their cell surface, which include
syndecans and glypicans [18–20]. Endothelial cells derived from rabbit aorta (EC)
express predominantly syndecan-4. HS is the main glycosaminoglycan synthesized
by these cells [21–23]. Acquisition of anoikis resistance leads to an increase in the
amount of HS and syndecan-4 synthesized by endothelial cells. Experimental
evidences suggest that heparan sulfate proteoglycan (HSPG) play a role in cell
spreading, cellular recognition, cellular adhesion and growth control [50–58]. In
addition, several reports describe high affinity association of heparin-like
molecules with growth factors [59–62], implying that heparan sulfate effects on
cell growth are likely to be mediated by growth factors [61–69]. Syndecan-4
mediates breast cancer cell adhesion and spreading [17] but also binds
proangiogenic growth factors and cytokines and modulates growth factor/growth
factor receptor interactions regulating angiogenic processes [70, 71].
Several studies have correlated the overexpression of syndecan-4 with increased
tumor cell proliferation [36, 37, 72]. Up-regulation of syndecan-4 is associated
with the development and metastasis of renal cell carcinoma, possibly by
increasing the cell migratory potential and survival through integrin-mediated
signaling [73]. Up-regulation of syndecan-4 has also been noted in hepatocellular
carcinomas and malignant mesotheliomas [34, 35]. Significant structural changes
of heparan sulfate and overexpression of syndecan-4 were observed in the EJ-ras-
transfected cells [21]. HS chains bind a multitude of proteins and ensure that a
wide variety of bioactive molecules (e.g., heparin-binding growth factors,
chemokines, lipoproteins, and enzymes) cling to the cell surface and ECM. HSPGs
can thus influence a variety of normal and pathologic processes, among which are
tissue repair, neurite outgrowth, inflammation and autoimmunity, tumor growth
and metastasis, vasculogenesis and angiogenesis [26, 74–77].
Because of the important and multifaceted roles of HSPGs in cell physiology,
their cleavage is likely to alter the integrity and functional state of tissues and to
provide a mechanism by which cells can respond rapidly to changes in the
Fig. 6. Expression of syndecan-4 and heparanase in EC, EJ-ras EC, Adh1-EC and Adh2-EC cells. (A) Representative RT-PCR products fractionated in
1% agarose gel electrophoresis and stained with ethidium bromide, showing bands of the expected sizes. (B) Expression of syndecan-4 detected by RT-
qPCR. GAPDH was used as a loading control. (C) The protein expression levels of syndecan-4 were assessed by western blot analysis. GAPDH is shown
as a protein loading control. Histogram depicting syndecan-4 protein levels normalized to GAPDH. (D) Flow cytometry analysis for cell surface presentation
of syndecan-4 in EC, EJ-ras EC, Adh1-EC and Adh2-EC cells. Filled histogram, cells treated with anti-syndecan-4 and secondary antibody; opened
histogram, cells treated only with secondary antibody. (E) Expression of heparanase detected by RT-qPCR. GAPDH was used as a loading control. In A, B
and E, the experiments were repeated four times. In C and D two independent experiments were performed in duplicates. EC: parental endothelial cells; EJ-
ras EC: EJ-ras transfected endothelial cells; Adh1-EC and Adh2-EC: anoikis-resistant endothelial cells. The bars represent the standard error. * P#0.05.
doi:10.1371/journal.pone.0116001.g006
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extracellular environment. Enzymatic degradation of HS is, therefore, likely to be
involved in fundamental biological phenomena, ranging from pregnancy,
morphogenesis, and development to inflammation, angiogenesis, and cancer
metastasis [78]. Heparanase is an endo-b-glucuronidase that is capable of
degrading heparan sulfate chains of proteoglycans, a key component of the
extracellular matrix and the basement membrane. The oligosaccharides so
generated lead to the release of a variety of bioactive molecules, such as growth
factors, chemotactic agents, and angiogenic agents, which are then deposited in
the extracellular matrix and basement membrane. These molecules can stimulate
cell proliferation, increase cell survival, and promote angiogenesis, morphogen-
esis, and vascularization [79, 80].
The expression of heparanase was investigated in EC–derived cell lines.
Anoikis-resistant endothelial cells show an increase in the expression of
heparanase. Most studies investigating heparanase have focused on its regulated
expression at different stages of cancer progression, and its overexpression in
tumor cells has also been reported to correlate with metastatic potential and
poorer prognosis [81, 82]. Heparanase and glycosaminoglycans can modulate
initial events of renal cell carcinoma development [83]. In bone tissue,
heparanase-1 overexpression creates a complex phenotype that typically results in
osteogenesis and increased bone mass [84].
The combined results provided evidences that increased syndecan-4 expression
and shedding may be modulated by increased expression of active heparanase
(50 kDa) in Adh1-EC and Adh2-EC cells. It was also described in the literature the
correlation between heparanase, metaloproteases and syndecan expression or
shedding [85, 86].
In conclusion, this study revealed that the acquisition of anoikis resistance
induced syndecan-4 up-regulation in endothelial cells. Acquisition of resistance to
anoikis is a potentially crucial step in endothelial cell transformation. A better
understanding of the mechanisms underlying anoikis resistance may provide
insight into the biology of cancer and identify novel therapeutic targets for
prevention of metastasis formation.
Supporting Information
S1 Fig. Expression of heparanase protein. The protein expression levels of
heparanase (HPSE) were assessed by western blot analysis. GAPDH is shown as a
protein loading control. Histogram depicting the ratio of active HPSE:pro-
enzyme HPSE (active HPSE:pro-enzyme HPSE/GAPDH). The experiment was
performed in duplicate and repeated twice. Active HPSE: 50 kDa; Pro-enzyme
HPSE: 65 kDa. EC: parental endothelial cells; EJ-ras EC: EJ-ras transfected
endothelial cells; Adh1-EC and Adh2-EC: anoikis-resistant endothelial cells.
doi:10.1371/journal.pone.0116001.s001 (TIF)
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